Biogen vows to fight CMS' draft coverage decision for Aduhelm before April finalization

Zachary Brennan

Senior Editor

Biogen executives made clear in an investor call Thursday they are not preparing to run a new CMS-approved clinical trial for their controversial Alzheimer’s drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen vows to fight CMS' draft coverage decision for Aduhelm before April finalization

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Bio­gen vows to fight CM­S' draft cov­er­age de­ci­sion for Aduhelm be­fore April fi­nal­iza­tion

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Biogen vows to fight CMS' draft coverage decision for Aduhelm before April finalization